Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spi...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9d799f0e15554e7aafc11f877069c7c0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9d799f0e15554e7aafc11f877069c7c0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9d799f0e15554e7aafc11f877069c7c02021-11-03T21:52:35ZTwo-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants2150-751110.1128/mBio.01813-21https://doaj.org/article/9d799f0e15554e7aafc11f877069c7c02021-10-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.01813-21https://doaj.org/toc/2150-7511 Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.Linda van OostenJort J. AltenburgCyrielle FougerouxCorinne GeertsemaFred van den EndWendy A. C. EversAdrie H. WestphalSimon LindhoudWilly van den BergDaan C. SwartsLaurens DeurhofAndreas SuhrbierThuy T. LeShessy Torres MoralesSebenzile K. MyeniMarjolein KikkertAdam F. SanderWillem Adriaan de JonghRobert DagilMorten A. NielsenAli SalantiMax SøgaardTimo M. P. KeijzerDolf WeijersMichel H. M. EppinkRené H. WijffelsMonique M. van OersDirk E. MartensGorben P. PijlmanAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 12, Iss 5 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Microbiology QR1-502 |
| spellingShingle |
Microbiology QR1-502 Linda van Oosten Jort J. Altenburg Cyrielle Fougeroux Corinne Geertsema Fred van den End Wendy A. C. Evers Adrie H. Westphal Simon Lindhoud Willy van den Berg Daan C. Swarts Laurens Deurhof Andreas Suhrbier Thuy T. Le Shessy Torres Morales Sebenzile K. Myeni Marjolein Kikkert Adam F. Sander Willem Adriaan de Jongh Robert Dagil Morten A. Nielsen Ali Salanti Max Søgaard Timo M. P. Keijzer Dolf Weijers Michel H. M. Eppink René H. Wijffels Monique M. van Oers Dirk E. Martens Gorben P. Pijlman Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants |
| description |
Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19. |
| format |
article |
| author |
Linda van Oosten Jort J. Altenburg Cyrielle Fougeroux Corinne Geertsema Fred van den End Wendy A. C. Evers Adrie H. Westphal Simon Lindhoud Willy van den Berg Daan C. Swarts Laurens Deurhof Andreas Suhrbier Thuy T. Le Shessy Torres Morales Sebenzile K. Myeni Marjolein Kikkert Adam F. Sander Willem Adriaan de Jongh Robert Dagil Morten A. Nielsen Ali Salanti Max Søgaard Timo M. P. Keijzer Dolf Weijers Michel H. M. Eppink René H. Wijffels Monique M. van Oers Dirk E. Martens Gorben P. Pijlman |
| author_facet |
Linda van Oosten Jort J. Altenburg Cyrielle Fougeroux Corinne Geertsema Fred van den End Wendy A. C. Evers Adrie H. Westphal Simon Lindhoud Willy van den Berg Daan C. Swarts Laurens Deurhof Andreas Suhrbier Thuy T. Le Shessy Torres Morales Sebenzile K. Myeni Marjolein Kikkert Adam F. Sander Willem Adriaan de Jongh Robert Dagil Morten A. Nielsen Ali Salanti Max Søgaard Timo M. P. Keijzer Dolf Weijers Michel H. M. Eppink René H. Wijffels Monique M. van Oers Dirk E. Martens Gorben P. Pijlman |
| author_sort |
Linda van Oosten |
| title |
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants |
| title_short |
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants |
| title_full |
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants |
| title_fullStr |
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants |
| title_full_unstemmed |
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants |
| title_sort |
two-component nanoparticle vaccine displaying glycosylated spike s1 domain induces neutralizing antibody response against sars-cov-2 variants |
| publisher |
American Society for Microbiology |
| publishDate |
2021 |
| url |
https://doaj.org/article/9d799f0e15554e7aafc11f877069c7c0 |
| work_keys_str_mv |
AT lindavanoosten twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT jortjaltenburg twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT cyriellefougeroux twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT corinnegeertsema twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT fredvandenend twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT wendyacevers twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT adriehwestphal twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT simonlindhoud twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT willyvandenberg twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT daancswarts twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT laurensdeurhof twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT andreassuhrbier twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT thuytle twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT shessytorresmorales twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT sebenzilekmyeni twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT marjoleinkikkert twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT adamfsander twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT willemadriaandejongh twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT robertdagil twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT mortenanielsen twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT alisalanti twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT maxsøgaard twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT timompkeijzer twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT dolfweijers twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT michelhmeppink twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT renehwijffels twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT moniquemvanoers twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT dirkemartens twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants AT gorbenppijlman twocomponentnanoparticlevaccinedisplayingglycosylatedspikes1domaininducesneutralizingantibodyresponseagainstsarscov2variants |
| _version_ |
1718445349052350464 |